Drugs / EBX-102
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06355583 Comparator | May 2024 → Feb 2026 overdue | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +1 | Imperial College London | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBX-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06355583 ↗ |